PROCEPT BioRobotics Co. (NASDAQ:PRCT) to Post Q2 2025 Earnings of ($0.42) Per Share, Leerink Partnrs Forecasts

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of PROCEPT BioRobotics in a research note issued on Thursday, March 28th. Leerink Partnrs analyst M. Kratky anticipates that the company will earn ($0.42) per share for the quarter. The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($2.00) per share.

PRCT has been the topic of a number of other reports. Wells Fargo & Company raised their target price on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 9th. Truist Financial increased their price objective on shares of PROCEPT BioRobotics from $55.00 to $58.00 and gave the company a "buy" rating in a research note on Wednesday, February 28th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $45.60.

PROCEPT BioRobotics Trading Up 1.2 %

PROCEPT BioRobotics stock traded up $0.58 during midday trading on Friday, reaching $49.42. The stock had a trading volume of 555,752 shares, compared to its average volume of 459,458. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -22.06 and a beta of 1.02. The company has a fifty day moving average of $48.47 and a 200 day moving average of $40.19. PROCEPT BioRobotics has a 52-week low of $24.83 and a 52-week high of $52.32. The company has a quick ratio of 6.77, a current ratio of 7.63 and a debt-to-equity ratio of 0.18.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.10). PROCEPT BioRobotics had a negative return on equity of 46.59% and a negative net margin of 77.75%. The firm had revenue of $43.58 million during the quarter, compared to analysts' expectations of $41.79 million. During the same period last year, the company earned ($0.56) earnings per share. The business's revenue for the quarter was up 83.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Amundi acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $37,000. Osaic Holdings Inc. grew its position in shares of PROCEPT BioRobotics by 31.0% in the second quarter. Osaic Holdings Inc. now owns 1,430 shares of the company's stock valued at $51,000 after purchasing an additional 338 shares during the period. O Dell Group LLC acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $68,000. UBS Group AG grew its position in shares of PROCEPT BioRobotics by 127.9% in the third quarter. UBS Group AG now owns 1,823 shares of the company's stock valued at $75,000 after purchasing an additional 1,023 shares during the period. Finally, Fairman Group LLC acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $84,000. Hedge funds and other institutional investors own 89.46% of the company's stock.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 16,000 shares of the firm's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $44.97, for a total value of $719,520.00. Following the completion of the transaction, the executive vice president now owns 47,351 shares of the company's stock, valued at $2,129,374.47. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Alaleh Nouri sold 16,000 shares of the firm's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $44.97, for a total transaction of $719,520.00. Following the completion of the transaction, the executive vice president now owns 47,351 shares of the company's stock, valued at $2,129,374.47. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Reza Zadno sold 9,179 shares of the firm's stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $46.67, for a total transaction of $428,383.93. Following the transaction, the chief executive officer now directly owns 246,710 shares of the company's stock, valued at approximately $11,513,955.70. The disclosure for this sale can be found here. Insiders sold a total of 127,459 shares of company stock worth $6,153,402 over the last three months. Corporate insiders own 19.60% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).